• Explore /
  • Videos & Slides
  • / Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Health-related quality of life (HRQoL) outcomes in the RATIONALE-305 study.

Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Health-related quality of life (HRQoL) outcomes in the RATIONALE-305 study.

Abstract Video & Slides Poster

Presenter

Marcia Cruz-Correa

Marcia Cruz-Correa, MD, PhD

University of Puerto Rico, School of Medicine

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Videos & Slides Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Clinical Trial Registration Number

NCT03777657

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 290)

DOI

10.1200/JCO.2024.42.3_suppl.290

Abstract #

290

Poster Bd #

D10

Abstract Disclosures

Similar Videos & Slides

Speaker: Markus H. Moehler, MD, PhD

Speaker: Eric Raymond, MD, PhD

Speaker: Samuel J Klempner, MD

Speaker: Lian Liu, MD, PhD